Metactive is developing innovative new medical devices for the treatment of neurovascular, peripheral vascular, and structural heart diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of arteries, veins, saccular aneurysms, left atrial appendages, and para-valvular leaks using detachable implants and highly flexible catheter delivery systems.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/08/18 | $1,200,000 | Series A |
Mid-America Angels Serra Ventures | undisclosed |
